Market Access
Week ending August 19, 2026
1. Access and affordability questions this week
- Pharmacy/formulary substitution — 6 questions/responses: Patients asked, “does substitution happen for Keytruda, and why/why not?” Responses repeatedly linked substitution to the prescription, insurer or health-system rules, pharmacy inventory, and prescriber authorization.
- Generic/biosimilar alternatives — 6 questions/responses: Patients asked whether Keytruda is “brand name only” or has an “equivalent generic/biosimilar.” Answers generally explained that Keytruda is a biologic and that availability and interchangeability vary by country and date.
- No direct cost, copay, prior-authorization, formulary-tier, patient-support, compounded, or off-label coverage questions appeared this week. The remaining questions focused on treatment positioning or product information and are outside this briefing’s access scope.
2. How substitution questions are being handled
The answers provide a useful baseline but are only partly actionable. They correctly frame substitution as dependent on plan rules, local policy, pharmacy stock, how the prescription is written, and whether the prescriber permits the change. For example, one response says substitution depends on “what your plan allows” and whether a biosimilar is “being stocked/covered in your area.”
However, most responses stop at general distinctions between a generic, biosimilar, and therapeutic alternative. They do not consistently give the patient a concrete next step, such as asking:
- Which exact product is being offered?
- Is it a formulary-mandated or inventory-driven substitution?
- Is the product covered under the patient’s benefit, and what will the patient owe?
- Does the prescriber need to approve or rewrite the order?
This distinction is important: a clinical-equivalence explanation does not establish pharmacy interchangeability, coverage, or affordability. The 13 biosimilar/generic tags across the dataset reinforce that this is a recurring access concept, although only 12 responses came from clearly access-relevant questions.
3. Off-label coverage risk visibility
No off-label-use questions or off_label tags were present. Accordingly, there is no evidence this week that AI is exposing—or failing to expose—coverage implications for off-label use.
4. Trend across weeks
This is a baseline week: prior-week data are unavailable. Substitution, off-label-coverage, and access-deflection trends cannot yet be classified as rising, falling, or steady. Hedging was frequent overall (50 tags across 60 responses), but it was not isolated to access questions.
5. Recommended actions
- Develop a patient-facing formulary-substitution FAQ covering biosimilar versus therapeutic alternative, insurer requirements, pharmacy stock, and prescriber approval.
- Add a short “what to ask next” checklist for patients offered something different at the pharmacy, including coverage and out-of-pocket questions.
- Validate current market-specific biosimilar/interchangeability content so AI-facing materials distinguish availability from automatic substitution.
- Begin tracking cost, prior authorization, formulary tier, and support-program queries separately to establish an access trend baseline.
- No off-label coverage action needed this week, because no such questions were observed.